• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications.

作者信息

El-Sharkawi Dima, Sud Amit, Prodger Catherine, Khwaja Jahanzaib, Shotton Rohan, Hanley Brian, Peacock Victoria, Peng Ying Ying, Arasaretnam Anita, Sharma Sarkhara, Aldridge Frances, Sharma Bhupinder, Wotherspoon Andrew, Cheung Betty, De Lord Corinne, Johnston Rosalynd, Kassam Shireen, Pettengel Ruth, Linton Kim, Greaves Paul, Cook Lucy, Naresh Kikkeri N, Cwynarski Kate, Eyre Toby A, Chau Ian, Cunningham David, Iyengar Sunil

机构信息

The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

出版信息

Blood Cancer J. 2023 Apr 18;13(1):54. doi: 10.1038/s41408-023-00827-5.

DOI:10.1038/s41408-023-00827-5
PMID:37072385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10113386/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c63c/10113386/fefcf0672987/41408_2023_827_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c63c/10113386/fefcf0672987/41408_2023_827_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c63c/10113386/fefcf0672987/41408_2023_827_Fig1_HTML.jpg

相似文献

1
A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications.在世界卫生组织（WHO）和国际癌症研究机构（ICC）新分类背景下对MYC重排弥漫性大B细胞淋巴瘤的回顾性研究
Blood Cancer J. 2023 Apr 18;13(1):54. doi: 10.1038/s41408-023-00827-5.
2
Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status.在BCL2和MYC表达状态背景下，使用Lymph2Cx检测法进行弥漫性大B细胞淋巴瘤细胞起源分类
Leuk Lymphoma. 2016;57(3):717-20. doi: 10.3109/10428194.2015.1072767. Epub 2015 Oct 5.
3
What does MYC, BCL2, and BCL6 genes 'rearranged' mean in large cell/diffuse B-cell lymphomas?在大细胞/弥漫性B细胞淋巴瘤中，MYC、BCL2和BCL6基因“重排”是什么意思？
Pathol Res Pract. 2022 Dec;240:154199. doi: 10.1016/j.prp.2022.154199. Epub 2022 Nov 2.
4
MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.MYC易位和拷贝数增加预示成人弥漫性大B细胞淋巴瘤（DLBCL）预后不良，尤其是生发中心样B细胞（GCB）型。
Histopathology. 2008 Aug;53(2):205-17. doi: 10.1111/j.1365-2559.2008.03076.x.
5
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.IGH-BCL2 和 MYC 同时重排的 B 细胞淋巴瘤是具有侵袭性的肿瘤，其临床和病理特征与 Burkitt 淋巴瘤和弥漫性大 B 细胞淋巴瘤不同。
Am J Surg Pathol. 2010 Mar;34(3):327-40. doi: 10.1097/PAS.0b013e3181cd3aeb.
6
Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.原发性中枢神经系统弥漫性大 B 细胞淋巴瘤的少见间变型。
Diagn Pathol. 2019 May 20;14(1):45. doi: 10.1186/s13000-019-0826-0.
7
Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.免疫表型对 Burkitt 淋巴瘤、双打击高级别 B 细胞淋巴瘤和单打击 MYC 重排弥漫性大 B 细胞淋巴瘤的研究和鉴别诊断的贡献。
Cytometry B Clin Cytom. 2020 Sep;98(5):412-420. doi: 10.1002/cyto.b.21887. Epub 2020 Jun 4.
8
Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.弥漫性大 B 细胞淋巴瘤中 MYC、BCL2 和/或 BCL6 额外拷贝的预后影响：与双/三打击淋巴瘤和双表达淋巴瘤的比较。
Diagn Pathol. 2019 Jul 17;14(1):81. doi: 10.1186/s13000-019-0856-7.
9
MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.MYC蛋白表达与原发性中枢神经系统弥漫性大B细胞淋巴瘤的不良预后相关。
APMIS. 2015 Jul;123(7):596-603. doi: 10.1111/apm.12390. Epub 2015 May 22.
10
Mutational landscape of high-grade B-cell lymphoma with , and/or rearrangements characterized by whole-exome sequencing.通过全外显子组测序对具有 和/或 重排的高级别 B 细胞淋巴瘤的突变景观进行分析。
Haematologica. 2022 Aug 1;107(8):1850-1863. doi: 10.3324/haematol.2021.279631.

引用本文的文献

1
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.自体移植或CAR-T作为挽救治疗后缓解的MYC重排大B细胞淋巴瘤患者巩固治疗的选择
Am J Hematol. 2025 Jul;100(7):1152-1162. doi: 10.1002/ajh.27687. Epub 2025 Apr 15.
2
Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report.使用戈利妥单抗成功治疗由滤泡性淋巴瘤转化而来的原发性难治性弥漫性大B细胞淋巴瘤/高级别B细胞淋巴瘤-MYC/BCL2：一例报告
Front Immunol. 2025 Mar 31;16:1566035. doi: 10.3389/fimmu.2025.1566035. eCollection 2025.
3

本文引用的文献

1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
2
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
3
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Clinical scoring systems, molecular subtypes and baseline [F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma.
用于弥漫性大B细胞淋巴瘤预后评估的临床评分系统、分子亚型及基线[F]FDG PET/CT图像分析
Cancer Imaging. 2024 Dec 18;24(1):168. doi: 10.1186/s40644-024-00810-8.
4
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data.基于基因测序数据的促增殖和抗凋亡特征量化的患者特异性计算模型可预测 B 细胞淋巴瘤的预后。
Blood Cancer J. 2024 Jul 4;14(1):105. doi: 10.1038/s41408-024-01090-y.
5
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma.在 II 期弥漫性大 B 细胞淋巴瘤中，MYC 重排是一个负预后因素，但在 I 期则不是。
Blood Cancer J. 2024 Jan 4;14(1):2. doi: 10.1038/s41408-023-00971-y.
泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
4
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.双打击和三打击淋巴瘤的一线治疗：来自回顾性多中心法国研究的生存和耐受性数据。
Am J Hematol. 2021 Mar 1;96(3):302-311. doi: 10.1002/ajh.26068. Epub 2020 Dec 29.
5
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.一线 R-CODOX-M/R-IVAC 化疗治疗高危弥漫性大 B 细胞淋巴瘤（IPI 3-5）的有利结局：英国 NCRI 试验的 2 期结果。
Ann Oncol. 2020 Sep;31(9):1251-1259. doi: 10.1016/j.annonc.2020.05.016. Epub 2020 May 26.
6
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.具有治疗意义的弥漫性大 B 细胞淋巴瘤遗传亚型的概率分类工具。
Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015.
7
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.弥漫性大 B 细胞淋巴瘤的靶向测序、分子亚型与结局：血液系统恶性肿瘤研究网络报告
Blood. 2020 May 14;135(20):1759-1771. doi: 10.1182/blood.2019003535.
8
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.高危细胞遗传学特征局限性侵袭性大 B 细胞淋巴瘤患者的结局。
Blood Adv. 2020 Jan 28;4(2):253-262. doi: 10.1182/bloodadvances.2019000875.
9
Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.弥漫性大 B 细胞淋巴瘤中重排和易位伙伴的预后意义：Lunenburg 淋巴瘤生物标志物联盟的研究。
J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.
10
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中体细胞核因子调控变异的全基因组发现
Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.